Cost efficiency and time savings are expected to drive market expansion in the near future at a CAGR of 15.00% during the forecast period from 2024 to 2032

Market Research Future (MRFR) has published on the “Global Drug Repurposing Market”. The Market is estimated to register a CAGR of 15.00% during the forecast period of 2024 to 2032.

Drug Repurposing Market Highlights

The global Drug Repurposing market is expected to register a CAGR of 15.00% during the forecast period and is estimated to reach USD 1.0 billion by 2032.

The global drug repurposing market is expanding as repurposed pharmaceuticals require less time to produce than novel chemical entities. Moreover, improvements in computational capacity for processing big databases have enabled cost-effective approaches to drug development. This accelerates the market's growth. However, a lack of understanding of the polypharmacological effects of medications, as well as a shortage of educated personnel, impedes market expansion. In contrast, a surge in collaboration between pharmaceutical corporations, academic research groups, and startups to promote medication repurposing operations is expected to generate profitable potential for market expansion.

Key Players

MRFR recognizes the following companies as key players in the global Drug Repurposing Market: Algernon Pharmaceuticals, Biovista, Celentyx Ltd, ChemBio Discovery, Inc., Chord Therapeutics SA, Excelra, Fios Genomics, Lantern Pharma, Inc., Novartis AG, Paradigm Biopharmaceuticals Ltd, Predictive Oncology, Segue Therapeutics, LLC, Sosei Group Corporation and Teva Pharmaceutical Industries.

Segment Analysis

The global Drug Repurposing Market has been segmented based on Types, Therapeutic Area, and Drug Molecules.

The Types segment the market into Disease-centric, Target-centric And Drug-centric. Disease-centric segment has the largest market share. Disease-specific repositioning tactics uncover linkages between preexisting and new symptoms considerably faster and more linearly than when applied to targets and medicines alone.

The Therapeutic Area segments the market into the Same Therapeutic Area And Different Therapeutic Area. The same therapeutic area category dominates the market due to rising medical costs and the slow rate of therapeutic discovery and development.

The Drug Molecules has divided the global Drug Repurposing Market into Biologics and Small Molecule. The biologics segment is predicted to increase rapidly during the projection period. Biotechnology and analytical technique developments have benefited the expansion of this market and are expected to continue to do so in the future.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Drug Repurposing Market Research Report

Regional Analysis

The global Drug Repurposing Market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe Drug Repurposing Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Drug Repurposing Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Drug Repurposing Market comprises of Middle East, Africa, and Latin America.

North America is the largest shareholder in the drug repositioning market. The region is a significant player in the pharmaceutical sector. The region is home to many of the world's major pharmaceutical businesses, conducts a considerable amount of drug research and development, and accounts for a sizable portion of the worldwide pharmaceutical market. This is attributable to a number of variables, including a strong healthcare infrastructure, significant R&D investments, a huge patient population, and a favorable regulatory climate.

Moreover, Europe is expected to have the greatest CAGR during the projection period, owing to the world's largest and fastest-growing marketplaces for pharmaceutical repurposing being located in Europe. The market is driven by factors such as the need for economical medicine development, a rise in the patient population, and increasing R&D investment. Several prominent academic institutions, pharmaceutical companies, and research institutes in Europe are actively involved in medication repurposing programmes. European regulatory organizations such as the European Medicines Agency (EMA) facilitate the approval of repurposed medicines. The region's advantageous regulatory framework for drug repurposing facilitates the research and commercialization of repurposed pharmaceuticals.

Additionally, the Asia Pacific region accounts for a significant portion of the worldwide drug repurposing market because of the swift rise in research and development endeavors. It is projected that easy bioavailability and cheap research costs will drive the market globally.

The rest of the world Drug Repurposing Market is segmented into three regions: the Middle East, Africa, and Latin America. These regions provide unexplored potential for medication repurposing. Increased healthcare spending, improved research infrastructure, and growing awareness of personalized medicine all provide prospects for drug repurposing projects in these areas.

Key Findings of the Study

• The global Drug Repurposing Market is expected to reach USD 1.0 billion by 2032, at a CAGR of 15.00% during the forecast period.


• Asia Pacific region accounts for a significant portion of the global drug repurposing market because of the swift rise in research and development endeavors.


• Disease-centric segment dominated the market in 2023 based on types segmentation.


• Algernon Pharmaceuticals, Biovista, Celentyx Ltd, ChemBio Discovery, Inc., Chord Therapeutics SA, Excelra, Fios Genomics, Lantern Pharma, Inc., Novartis AG, Paradigm Biopharmaceuticals Ltd, Predictive Oncology, Segue Therapeutics, LLC, Sosei Group Corporation and Teva Pharmaceutical Industries are key market players.